In that study, researchers looked at the data from two already completed studies, the Vioxx Gastrointestinal Outcomes Research study (VIGOR) and Celecoxib Long-Term Arthritis Safety Study (CLASS), and concluded that both drugs might slightly increase the risk of cardiac events such as heart attack and stroke.

FORBES: Magazine Article